# Prospective Population Study of Women in Gothenburg

https://neurodegenerationresearch.eu/survey/prospective-population-study-of-women-in-gothenburg/ Title of the cohort

Prospective Population Study of Women in Gothenburg

# Acronym for cohort

PPSW

# Name of Principal Investigator

Title Professor

First name Ingmar

Last name Skoog

# Address of institution where award is held

Institution Neuroscience and Physiology, Neuropsychiatric Epidemiology, Gothenburg University Street Address Wallinsgatan 6

City

Postcode SE-431 41

# Country

• Sweden

# Website

www.epinep.gu.se

# **Contact email**

ingmar.skoog@neuro.gu.se

# **Funding source**

- 1) The Swedish Research Council (VR).
- 2) Swedish Council for Working Life and Social Research (FAS).
- 3) US Alzheimer Association.

# 1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer's disease and other dementias
- Neurodegenerative disease in general

# When studies on the above condition(s) are expected to become possible

• Already possible

### 2a. Stated aim of the cohort

To study dementia, other mental disorders (depression, psychotic disorders, anxiety disorders), suicidal behaviour and cognitive function in women followed from 1968-2011

### 2b. Features distinguishing this cohort from other population cohorts

The long follow-up

### 3a. i) Number of publications that involve use of cohort to date

100

### 3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study) 3b. Publication list/link to where data or publications are accessible (if available)

www.epinep.gu.se

# **3c.** Information (i.e. research findings) expected to be gained from the population cohort 4a. Study criteria: age range of participants at recruitment

Age in years from: 38

To ('until death' if applicable): 60

### 4b. Study criteria: inclusion criteria

Women born 1908, 1914, 1918, 1922 and 1930 on certain dates and living in Gothenburg, Sweden 1968

### 4c. Study criteria: exclusion criteria

none

# 5. Size of the cohort (i.e. number of participants enrolled)

• 1,000 - 5,000 participants

### 6a. Measures used to characterise participants

psychiatric examinations, close informant interviews, psychometric testings, personality inventories, physical examinations, DNA-analyses, comprehensive laboratory tests, CT-scan of the head, cerebrospinal fluid analyses, psychosocial factors, functional ability, and case record studies. See also www.epinep.gu.se

# 6b. Additional measures for participants with a clinical disorder 6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

Dementia and other mental disorders

# 7. Study design

- Prospective cohort
- Longitudinal
- Cross sectional survey

### 8. Cases matched by

- Other health assessment (specify) / N/A
  - representative sample

### 9a. Does the study include a specialised subset of control participants

• No

# 9b. If yes, description of specialised subset of control participants 10a. i) Data collection start date

01-01-1968

### 10a. ii) Data collection end date

31-12-2025

### 10a iii) Data collection for this study is

- Data collection ongoing
- Data analysis ongoing

# 10b. Plans to continue the cohort study beyond the current projected end date

- Yes funding applied for
- Yes intend to apply for funding

### 11. Data collected

Through links to medical records

### 12. System in place to enable re-contact with patients for future studies

• Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

### 13a. Format and availability of data stored in a database

Yes/No % available

Data summarised in database	Yes	100
Database is web-based	No	
Database on spreadsheet	Yes	100
Database is on paper	Yes	100
Other (specify)		

# Language used:

### Swedish

# 13b. Format and availability of data held as individual records

Yes/No % availableData held as individual recordsYes100Data is web-basedNoNoData held on computer based recordsYes100Data held on cardsNoNoOther (specify)VesVes

### Language used:

swedish

### 14a. Are data available to other groups

Yes

# 14b. Access policy/mechanisms for access if data are available to other groups

- Apply to PI or co-ordinator at resource
- Access through collaboration with PI only

### 15. Data sharing policy specified as a condition of use

• No requirement to make data publicly available

# 16a. Are tissues/samples/DNA available to other groups

Yes

### 16b. i) Description of available tissues/samples/DNA

- Living donors:blood
- Living donors: blood derivatives
- Living donors: DNA
- Living donors: cerebro-spinal fluid

# 16b. ii) Form available tissues/samples/DNA are supplied in

- Primary samples: Supplied fresh
- Primary Samples: Stabilised samples (frozen or fixed)
- Secondary samples: plasma

• Secondary samples: DNA

# 16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

Yes

# 17. Is information on biological characteristics available to other groups

• Yes, for all the cohort